DE69943222D1 - Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b - Google Patents
Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa bInfo
- Publication number
- DE69943222D1 DE69943222D1 DE69943222T DE69943222T DE69943222D1 DE 69943222 D1 DE69943222 D1 DE 69943222D1 DE 69943222 T DE69943222 T DE 69943222T DE 69943222 T DE69943222 T DE 69943222T DE 69943222 D1 DE69943222 D1 DE 69943222D1
- Authority
- DE
- Germany
- Prior art keywords
- human
- kappa
- modulation
- compositions
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21006098A | 1998-12-10 | 1998-12-10 | |
PCT/US1999/029371 WO2000034447A2 (en) | 1998-12-10 | 1999-12-09 | Human ubiquitin ligase e3 for the modulation of nf-kappa b |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69943222D1 true DE69943222D1 (de) | 2011-04-07 |
Family
ID=22781444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69943222T Expired - Lifetime DE69943222D1 (de) | 1998-12-10 | 1999-12-09 | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b |
Country Status (12)
Country | Link |
---|---|
US (4) | US6656713B2 (de) |
EP (1) | EP1135504B1 (de) |
JP (1) | JP4633259B2 (de) |
KR (2) | KR100756689B1 (de) |
CN (2) | CN102816743A (de) |
AT (1) | ATE499445T1 (de) |
AU (2) | AU779893B2 (de) |
CA (1) | CA2354153C (de) |
DE (1) | DE69943222D1 (de) |
ES (1) | ES2361660T3 (de) |
IL (3) | IL143516A0 (de) |
WO (1) | WO2000034447A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4695735B2 (ja) * | 1996-08-26 | 2011-06-08 | シグナル ファーマシューティカルズ, エルエルシー | 刺激誘導性I(κ)Bキナーゼ[IKK]シグナルソーム |
ATE499445T1 (de) * | 1998-12-10 | 2011-03-15 | Signal Pharm Llc | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b |
WO2002011672A2 (en) * | 2000-08-07 | 2002-02-14 | Deltagen, Inc. | Transgenic mice containing ubiquitin protein ligase e3 gene disruptions |
EP1182251A1 (de) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Verfahren zum Identifizieren von Verbindungen, die die Ubiquitin vermittelte Proteolyse von IkB inhibieren |
EP1343816A2 (de) * | 2000-12-18 | 2003-09-17 | Hybrigenics | Proteine, die mit trcp interagieren |
US7037936B2 (en) | 2002-06-17 | 2006-05-02 | Signal Pharmaceuticals, Llc. | Compounds useful for the treatment of cancer, compositions thereof and methods therewith |
US20060256599A1 (en) * | 2005-03-22 | 2006-11-16 | Malin Patricia J | Database of electronically profiled cells and methods for generating and using same |
US20100292306A1 (en) * | 2005-05-24 | 2010-11-18 | Carlson C George | Compositions And Methods For The Treatment Of Muscular Dystrophy |
DE602006014519D1 (de) | 2005-12-16 | 2010-07-08 | Nat Cancer Ct | Peptide zur transglutaminase-hemmung |
WO2007101202A1 (en) * | 2006-02-27 | 2007-09-07 | Research Development Foundation | Cell-targeted ikb and methods for the use thereof |
GB201110938D0 (en) * | 2011-06-27 | 2011-08-10 | Iti Scotland Ltd | Compounds |
US20130210875A1 (en) * | 2012-02-10 | 2013-08-15 | Macau University Of Science And Technology | Novel binding site of IKK-beta |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US5519003A (en) | 1994-02-01 | 1996-05-21 | Board Of Trustees Of The Leland Stanford Junior University | WD-40-derived peptides and uses thereof |
US5597898A (en) | 1995-02-15 | 1997-01-28 | Yale University | NF-κB activation regulatory protein, IκB-β |
JP4695735B2 (ja) * | 1996-08-26 | 2011-06-08 | シグナル ファーマシューティカルズ, エルエルシー | 刺激誘導性I(κ)Bキナーゼ[IKK]シグナルソーム |
US5972674A (en) | 1996-08-26 | 1999-10-26 | Signal Pharmaceuticals, Inc. | Stimulus-inducible protein kinase complex and methods of use therefor |
US5932425A (en) * | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
US6235512B1 (en) | 1997-07-01 | 2001-05-22 | Tularik Inc. | IKK-α proteins, nucleic acids and methods |
US5851812A (en) | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
US6242253B1 (en) | 1997-10-09 | 2001-06-05 | Regents Of The University Of California | IkB kinase, subunits thereof, and methods of using same |
US6573094B1 (en) * | 1997-10-16 | 2003-06-03 | Baylor College Of Medicine | F-box genes and proteins |
FR2774378A1 (fr) * | 1998-01-30 | 1999-07-30 | Inst Nat Sante Rech Med | PROTEINE HUMAINE BETA-TrCP DE CIBLAGE DES PROTEINES VERS LES VOIES DE DEGRADATION PAR LE PROTEASOME |
ATE499445T1 (de) * | 1998-12-10 | 2011-03-15 | Signal Pharm Llc | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b |
US6280623B1 (en) * | 1999-03-23 | 2001-08-28 | Hsien-Chih Ma | Differential and continuous separation apparatus with controlled parameters for solids and liquids |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
-
1999
- 1999-12-09 AT AT99966122T patent/ATE499445T1/de not_active IP Right Cessation
- 1999-12-09 DE DE69943222T patent/DE69943222D1/de not_active Expired - Lifetime
- 1999-12-09 ES ES99966122T patent/ES2361660T3/es not_active Expired - Lifetime
- 1999-12-09 JP JP2000586881A patent/JP4633259B2/ja not_active Expired - Fee Related
- 1999-12-09 WO PCT/US1999/029371 patent/WO2000034447A2/en active Application Filing
- 1999-12-09 CA CA2354153A patent/CA2354153C/en not_active Expired - Fee Related
- 1999-12-09 CN CN2012100910402A patent/CN102816743A/zh active Pending
- 1999-12-09 EP EP99966122A patent/EP1135504B1/de not_active Expired - Lifetime
- 1999-12-09 AU AU21740/00A patent/AU779893B2/en not_active Ceased
- 1999-12-10 KR KR1020017007719A patent/KR100756689B1/ko not_active IP Right Cessation
- 1999-12-10 IL IL14351699A patent/IL143516A0/xx unknown
- 1999-12-10 CN CN99814307A patent/CN1346406A/zh active Pending
- 1999-12-10 KR KR1020077010016A patent/KR20070050995A/ko not_active Application Discontinuation
-
2001
- 2001-04-09 US US09/832,161 patent/US6656713B2/en not_active Expired - Fee Related
- 2001-05-31 IL IL143516A patent/IL143516A/en not_active IP Right Cessation
-
2003
- 2003-09-19 US US10/665,715 patent/US7186503B2/en not_active Expired - Fee Related
-
2004
- 2004-12-20 AU AU2004240212A patent/AU2004240212B2/en not_active Ceased
-
2007
- 2007-01-25 US US11/698,848 patent/US7414120B2/en not_active Expired - Fee Related
- 2007-11-08 IL IL187254A patent/IL187254A/en not_active IP Right Cessation
-
2008
- 2008-08-08 US US12/189,048 patent/US8263326B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2354153C (en) | 2011-04-12 |
ATE499445T1 (de) | 2011-03-15 |
US20070208167A1 (en) | 2007-09-06 |
JP2002539766A (ja) | 2002-11-26 |
WO2000034447A2 (en) | 2000-06-15 |
IL187254A (en) | 2010-12-30 |
WO2000034447A3 (en) | 2000-11-09 |
AU779893B2 (en) | 2005-02-17 |
US7186503B2 (en) | 2007-03-06 |
WO2000034447A9 (en) | 2002-08-29 |
WO2000034447A8 (en) | 2001-07-12 |
US20040203098A1 (en) | 2004-10-14 |
US20030166587A1 (en) | 2003-09-04 |
KR20020007284A (ko) | 2002-01-26 |
US20090233855A1 (en) | 2009-09-17 |
US8263326B2 (en) | 2012-09-11 |
AU2174000A (en) | 2000-06-26 |
CN1346406A (zh) | 2002-04-24 |
JP4633259B2 (ja) | 2011-02-16 |
CA2354153A1 (en) | 2000-06-15 |
AU2004240212A8 (en) | 2005-02-10 |
AU2004240212B2 (en) | 2007-12-06 |
KR100756689B1 (ko) | 2007-09-07 |
IL143516A (en) | 2010-11-30 |
CN102816743A (zh) | 2012-12-12 |
EP1135504A2 (de) | 2001-09-26 |
US6656713B2 (en) | 2003-12-02 |
KR20070050995A (ko) | 2007-05-16 |
US7414120B2 (en) | 2008-08-19 |
EP1135504B1 (de) | 2011-02-23 |
AU2004240212A1 (en) | 2005-02-10 |
IL143516A0 (en) | 2002-04-21 |
ES2361660T3 (es) | 2011-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
DE69939864D1 (de) | Ppar-gamma modulatoren | |
ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
IL138476A0 (en) | Method for treating pharmaceutical compositions by special use of anti-oxidant | |
ATE253631T1 (de) | Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren | |
DE69839326D1 (de) | ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB | |
DE69435096D1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
PL328858A1 (en) | Immunogenous peptides | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
ATE255632T1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
HK1037722A1 (en) | Modulating multiple lineage kinase proteins. | |
DE58906239D1 (de) | Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn. | |
DE69626816D1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
ATE246924T1 (de) | Neue therapeutische verwendung von nicergoline | |
WO2002014536A3 (en) | Odulating multiple lineage kinase proteins | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
NO984189L (no) | FremgangsmÕte for behandling av bipolar forstyrrelse | |
DE59805246D1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
DE69110861T2 (de) | Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung. | |
DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
DE60007864D1 (de) | Verwendung von antileukoprotease zur behandlung von endometriose | |
WO2003023048A3 (en) | METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) | |
ATE272406T1 (de) | Prognose von ptp lar vermittelten krankheiten | |
UA31270A (uk) | Спосіб формування товстокишкового анастомозу | |
UA32146A (uk) | Спосіб оцінки ефективності лікування пародонтита |